KRAS and neoplasm: In fact, RCC2 was found to be an independent prognostic biomarker in multivariable analysis of chemotherapy-untreated stage I–III patients, after adjusting for TNM stage, patient age, sex, tumour location, MSI status, CDX2 expression, BRAFV600E- and KRAS mutation status.